دورية أكاديمية
The role of interleukin-13 in chronic inflammatory intestinal disorders
| العنوان: | The role of interleukin-13 in chronic inflammatory intestinal disorders |
|---|---|
| المؤلفون: | Giuffrida P., Caprioli F., Facciotti F., Di Sabatino A. |
| المساهمون: | P. Giuffrida, F. Caprioli, F. Facciotti, A. Di Sabatino |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2019 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Celiac disease, Crohn's disease, Experimental coliti, Type 2 immunity, Ulcerative colitis, Animal, Chronic Disease, Human, Immunity, Innate, Inflammatory Bowel Disease, Interleukin-13, Intestinal Mucosa, Lymphocyte, Mice, Natural Killer T-Cell, Th2 Cells, Settore MED/12 - Gastroenterologia, Settore MED/09 - Medicina Interna |
| الوصف: | Interleukin (IL)-13 is a cytokine playing a pivotal role in T helper (Th)2 immune response supposed to be implicated in some intestinal disorders. IL-13 is produced by Th2 cells, natural killer T cell, innate lymphoid cells and innate immune cells, which contribute to trigger and maintain a chronic idiopathic intestinal inflammation. In murine models IL-13 exerts pleiotropic functions, playing either pathogenic or protective roles according to the different experimental conditions. As regards celiac disease, IL-13 is considered to be involved mostly in the refractory phase rather than at uncomplicated stage. Discrepancies have been observed in the role of IL-13 upon the inflammation and fibrosis in ulcerative colitis (UC) and in Crohn's disease, respectively. Failure of the anti-IL-13 monoclonal antibodies tralokinumab and anrukinzumab in UC patients in clinical trials support the absence of a role for IL-13 in UC. This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn's disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/30844559; info:eu-repo/semantics/altIdentifier/wos/WOS:000466452500012; volume:18; issue:5; firstpage:549; lastpage:555; numberofpages:7; journal:AUTOIMMUNITY REVIEWS; http://hdl.handle.net/2434/653354Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85062620478 |
| DOI: | 10.1016/j.autrev.2019.03.012 |
| الإتاحة: | https://doi.org/10.1016/j.autrev.2019.03.012Test http://hdl.handle.net/2434/653354Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.61E2E8FA |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.autrev.2019.03.012 |
|---|